Business
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth.\n\n\nAcross nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strategy.\n\n\nANTICIPATED PIPELINE MILESTONES\n\n\n\nQ3 2025 - Phase 2 study initiation for ACP-204 in Lewy Body Dementia Psychosis (LBDP)\n\n\n\nQ3 2025 - Phase 3 study initiation in Japan for trofinetide in Rett syndrome\n\n\n\nEarly Q4 2025 - Topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome (PWS) following the recent completion of enrollment\n\n\n\nQ4 2025 - Phase 2 study initiation for ACP-211 in major depressive disorder (MDD)\n\n\n\nQ4 2025 - First in human study of ACP-271 in healthy volunteers\n\n\n\nQ1 2026 - Potential approval from European Medicines Agency for trofinetide\n\n\n\nMid-2026 - Topline results from ACP-204 Phase 2 study in Alzheimer’s disease psychosis (ADP)\n\n\n\n2026 - Phase 2 study initiation for ACP-711 in Essential Tremor (ET)\n\n\n\n“Acadia is building from a position of strength, with two commercial franchises on track to deliver over $1 billion in net sales this year,” said Catherine Owen Adams, Chief Executive Officer. “As we advance our pipeline, the five molecules we showcase today represent a multibillion-dollar incremental revenue opportunity. They also underscore our unwavering commitment to bold science and our focus on delivering transformative therapies for patients with serious and underserved neurological and rare diseases. We believe the opportunity ahead is extraordinary—and we are confident in our ability to execute with discipline and purpose as we work to build a biotech powerhouse.”\n\n\n“At Acadia, we’re building a strong, sustainable pipeline focused on progressing the most promising science with the goal of meaningfully improving patient care,” said Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of R&D. “Our pipeline is moving forward with real momentum. Between now and the end of 2026, we plan to initiate seven Phase 2 or 3 studies, with fiv...